01 Increasing Adoption of Highly Sensitive Molecular Diagnostics A key market trend stems from the growing adoption of highly sensitive molecular diagnostic technologies for malaria detection, particularly in settings where parasite levels are low. Conventional rapid diagnostic tests and microscopy can have limitations in detecting low-parasitemia and asymptomatic infections, increasing demand for PCR, LAMP, and other nucleic-acid-based methods. These technologies provide higher sensitivity and support malaria surveillance and elimination efforts by identifying infections that may otherwise remain undetected. For example, LAMP-based malaria diagnostic technologies are being used to enable sensitive parasite detection with relatively simple equipment in resource-limited settings.
02 Expansion of AI-enabled Digital Microscopy AI-enabled systems can automate blood smear analysis, identify Plasmodium parasites, and support parasite density assessment, reducing dependence on highly skilled microscopists. This transition is helping improve diagnostic consistency and expand testing capabilities in regions facing shortages of trained laboratory personnel. For example, Noul’s miLab integrates automated blood-smear preparation, staining, imaging, and AI-based parasite analysis to support malaria diagnosis.
01 The malaria diagnostics market has substantial exposure to supply chain disruptions, particularly due to dependence on specialized raw materials, diagnostic reagents, test components, manufacturing capacity, and international procurement networks. Supply interruptions, logistics constraints, shortages of critical components, and fluctuations in transportation and procurement costs are reshaping the market ecosystem by affecting product availability, delivery timelines, inventory management, and procurement programs across malaria-endemic regions globally. The market is expected to follow a stair-step recovery, with gradual improvements as supply availability normalizes, manufacturers rebuild inventories, procurement channels stabilize, and regional production capacity expands.
01 The malaria diagnostics market forecasts sustained investments directed toward next-generation rapid diagnostic tests, digital test readers, ultrasensitive parasite detection, and data-enabled malaria surveillance technologies, with funders increasingly supporting tools that improve diagnostic accuracy and real-time disease mapping in low-resource settings.
02 Key Investment and Funding Activities for Malaria Diagnostics Market, 2025–2026 Entity Investment/Funding (USD) Details Gates Foundation USD 0.75 Million In June 2026, Broad Institute receive funds from the Gates Foundation for the development of pathogen genomic-data analysis pipelines for malaria and other public-health pathogens in Africa. Gates Foundation USD 2.31 Million In March 2026, the Gates Foundation funded Sproxil for the development of a near-real-time malaria RDT positivity map using each diagnostic test as a digital surveillance data point. Gates Foundation USD 4.59 Million In November 2025, Audere received funding from the Gates Foundation for the adoption of digital rapid diagnostic-test readers to improve malaria diagnostic data and quality of care in LMICs. Gates Foundation USD 0.50 Million In November 2025, Wondfo Biotech received funding for improving access to affordable, high-sensitivity malaria diagnostic tools for public-health programs in African LMICs. Gates Foundation USD 0.20 Million In October 2025, IIT Kanpur received funds fo the development of low-cost, miniaturized biosensors for malaria and neonatal-health diagnostics in low-resource settings. GHIT Fund USD 1.0 Million In January 2025, the GHIT Fund was given to Ehime University, Nagasaki University, Universiti Malaysia Sabah for the development of ultrasensitive, robust malaria rapid diagnostic tests using de novo antigen binders. GHIT Fund USD 0.65 Million In January 2025, the ZOO-RDT project received USD 0.65 million to validate a new biomarker and reagents for diagnosing acute zoonotic malaria in Southeast Asia.
01 Increasing Need for Species-Specific and Drug Resistance Detection and Expansion of Malaria Elimination and Active Case Detection Programs Drive the Market The growing need to differentiate Plasmodium species and identify infections that may respond differently to antimalarial treatment is increasing demand for advanced malaria diagnostic technologies. Conventional rapid diagnostic tests primarily detect malaria antigens, while molecular and specialized diagnostic methods can provide more detailed information for difficult-to-diagnose or low-parasitemia infections. The spread of P. falciparum and P. vivax across different geographic regions is encouraging healthcare systems to adopt diagnostic approaches that support accurate species identification and treatment decisions. This growing emphasis on diagnostic precision is supporting demand for advanced malaria testing solutions and driving market growth.The shift from routine passive diagnosis toward active case detection and elimination-focused screening is creating additional demand for malaria diagnostics in areas with declining transmission. As countries move closer to malaria elimination, health authorities need to identify asymptomatic, imported, and low-density infections that may otherwise remain undetected and contribute to continued transmission. This increases the need for repeated screening across high-risk communities, border regions, migrant populations, and outbreak-prone locations. For example, malaria elimination programs conduct targeted screening around identified cases and in high-risk communities to locate additional infections and interrupt transmission chains.
01 High Dependence on Imported Diagnostic Supplies and Species & Biomarkers Variability Restrain Market Expansion Many malaria-endemic countries depend on international manufacturers and procurement programs for rapid diagnostic tests, reagents, microscopy supplies, and other diagnostic consumables. Disruptions in international procurement, transportation delays, funding changes, or shortages of key diagnostic products can affect the consistent availability of tests in local healthcare facilities. This is particularly challenging for national malaria programs that require continuous supplies for seasonal campaigns and routine case management.The presence of different malaria species and variation in their detectable biomarkers makes it difficult for healthcare programs to use a single RDT format across all endemic settings. RDT selection may need to consider whether testing must detect P. falciparum, P. vivax, or non-falciparum infections, as well as which antigens are targeted by the test. This creates additional product-selection and procurement requirements for national malaria programs operating across regions with different parasite profiles.
01 Expansion of Molecular Surveillance for Antimalarial Drug Resistance and G6PD Testing Offer Growth Opportunities to Market Players The increasing spread and monitoring of antimalarial drug resistance is creating opportunities for molecular diagnostic companies to provide tests that identify resistance-associated genetic markers alongside malaria infection. Molecular diagnostics can detect low-density infections and support genotyping and detection of drug-resistance mutations, making them valuable for national surveillance and malaria elimination programs. This creates opportunities for molecular diagnostic developers and specialized laboratories to provide PCR and sequencing-based surveillance solutions as countries strengthen resistance monitoring.The wider use of 8-aminoquinoline medicines such as primaquine and tafenoquine for P. vivax radical cure is creating an opportunity for diagnostic companies to combine malaria detection with G6PD testing. G6PD deficiency can cause severe hemolysis when these medicines are used without appropriate assessment, increasing the need for reliable G6PD status before treatment. The WHO recommends G6PD testing before the use of tafenoquine and recommends testing to guide primaquine treatment in appropriate settings. This creates an opportunity for manufacturers to develop integrated malaria-plus-G6PD testing platforms for clinics and malaria programs.
01 Diagnostic Inaccuracy and High Sensitivity with Field Usability Challenges Market Growth A key challenge for the malaria diagnostics market is maintaining consistent diagnostic performance across regions with different Plasmodium species, parasite densities, and antigen characteristics. The emergence of P. falciparum strains with pfhrp2/3 gene deletions can reduce the performance of HRP2-based rapid diagnostic tests, while low-density infections can remain difficult to detect using conventional methods. Diagnostic manufacturers therefore need to continuously validate products against changing parasite populations and geographic conditions, increasing development, surveillance, and quality-control requirements.Molecular techniques can detect infections missed by microscopy and conventional RDTs, but they often require more equipment, controlled testing environments, and skilled personnel. Manufacturers therefore face difficulty in combining laboratory-level sensitivity with the simplicity and portability required for community-based testing. This creates a trade-off between diagnostic performance and scalability, particularly in elimination-focused programs.
April 2026 Rapigen Inc. received WHO prequalification for three malaria RDTs: BIOCREDIT Malaria Ag Pf (pLDH), BIOCREDIT Malaria Ag Pf (pLDH/HRPII), and BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH).